Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
KZR
$6.74
$
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Next Earnings
2026-02-25
Beta
0.553
Average Volume
Market Cap
Last Dividend
CIK
0001645666
ISIN
US49372L2097
CUSIP
49372L100
CEO
Christopher J. Kirk
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
55
IPO Date
2018-06-21
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| BML Capital Management LLC Has $2.81 Million Holdings in Kezar Life Sciences, Inc. $KZR | BML Capital Management LLC boosted its holdings in Kezar Life Sciences, Inc. (NASDAQ: KZR) by 13.5% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 720,787 shares of the company's stock after buying an additional 85,604 shares during the period. Kezar Life Sciences accounts for | Defense World | 2026-02-23 04:23:00 |
| Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives Consensus Rating of “Reduce” from Analysts | Shares of Kezar Life Sciences, Inc. (NASDAQ: KZR - Get Free Report) have been given an average rating of "Reduce" by the six research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating and four have given a hold rating to the company. The average | Defense World | 2026-02-19 03:29:05 |
| Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune. | Business Wire | 2026-01-09 06:01:00 |
| Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know | Kezar Life Sciences (KZR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | Zacks Investment Research | 2026-01-05 13:00:18 |
| Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives Average Recommendation of “Reduce” from Brokerages | Shares of Kezar Life Sciences, Inc. (NASDAQ: KZR - Get Free Report) have received an average recommendation of "Reduce" from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and four have given a hold rating to the company. The | Defense World | 2025-12-31 01:26:58 |
| Reviewing Dyadic International (NASDAQ:DYAI) and Kezar Life Sciences (NASDAQ:KZR) | Dyadic International (NASDAQ: DYAI - Get Free Report) and Kezar Life Sciences (NASDAQ: KZR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation. Profitability This table compares Dyadic International | Defense World | 2025-12-03 02:20:44 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13G/A | 2026-02-09 | 2026-02-09 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-07 | 2025-11-07 | View Filing |
| 8-K | 2025-10-22 | 2025-10-22 | View Filing |
| 8-K | 2025-10-16 | 2025-10-16 | View Filing |
| SC 13G | 2025-09-08 | 2025-09-08 | View Filing |
| 10-Q | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| 4 | 2025-07-03 | 2025-07-03 | View Filing |
| 4 | 2025-07-03 | 2025-07-03 | View Filing |
| 4 | 2025-07-01 | 2025-07-01 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 8-K | 2025-06-23 | 2025-06-23 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| ARS | 2025-04-25 | 2025-04-25 | View Filing |
| DEFA14A | 2025-04-25 | 2025-04-25 | View Filing |
| DEF 14A | 2025-04-25 | 2025-04-25 | View Filing |
| 3 | 2025-04-16 | 2025-04-16 | View Filing |
| 3 | 2025-04-16 | 2025-04-16 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 8-K | 2025-04-01 | 2025-04-01 | View Filing |
| S-8 | 2025-03-25 | 2025-03-25 | View Filing |
| 10-K | 2025-03-25 | 2025-03-25 | View Filing |
| 8-K | 2025-03-25 | 2025-03-25 | View Filing |
| SC 13G/A | 2025-03-21 | 2025-03-21 | View Filing |
| SC 13G | 2025-03-06 | 2025-03-06 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| SC 13D/A | 2025-03-03 | 2025-03-03 | View Filing |
| 8-K | 2025-02-27 | 2025-02-27 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| EFFECT | 2025-02-11 | 2025-02-11 | View Filing |
| S-3 | 2025-02-05 | 2025-02-05 | View Filing |
| SC 13D/A | 2025-01-16 | 2025-01-16 | View Filing |
| 4 | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2025-01-13 | 2025-01-13 | View Filing |
| 8-K | 2025-01-10 | 2025-01-10 | View Filing |
| 8-K | 2024-12-03 | 2024-12-03 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| 8-A12B/A | 2024-10-29 | 2024-10-29 | View Filing |
| 8-K | 2024-10-28 | 2024-10-28 | View Filing |
| 8-A12B | 2024-10-17 | 2024-10-17 | View Filing |
| 8-K | 2024-10-17 | 2024-10-17 | View Filing |
| 8-K | 2024-10-10 | 2024-10-10 | View Filing |
| SC 13D | 2024-10-08 | 2024-10-08 | View Filing |
| 8-K | 2024-10-04 | 2024-10-04 | View Filing |
| 8-K | 2024-09-30 | 2024-09-30 | View Filing |
| 10-Q | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-13 | 2024-08-13 | View Filing |
| 4 | 2024-07-26 | 2024-07-26 | View Filing |
| SC 13G/A | 2024-07-08 | 2024-07-08 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 8-K | 2024-06-21 | 2024-06-21 | View Filing |
| 8-K | 2024-06-04 | 2024-06-04 | View Filing |
| 10-Q | 2024-05-09 | 2024-05-09 | View Filing |
| 8-K | 2024-05-09 | 2024-05-09 | View Filing |
| ARS | 2024-04-26 | 2024-04-26 | View Filing |
| DEFA14A | 2024-04-26 | 2024-04-26 | View Filing |
| DEF 14A | 2024-04-26 | 2024-04-26 | View Filing |
| PRE 14A | 2024-04-16 | 2024-04-16 | View Filing |
| 424B5 | 2024-03-22 | 2024-03-22 | View Filing |
| S-8 | 2024-03-14 | 2024-03-14 | View Filing |
| 10-K | 2024-03-14 | 2024-03-14 | View Filing |
| 8-K | 2024-03-14 | 2024-03-14 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Volume Gap | 56.09% | 1.05 | 39 | 1.26 | 1.38 | 30.54 |
| Adaptive Wave | 40.61% | 1 | 1 | 0.7 | 0.33 | 15.06 |
| Donchian Channel Strategy | 29.13% | 1.07 | 25 | 0.74 | 0.34 | 3.58 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxx% | xxxx | x | xxxx | x | xxxx |
| xxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |